



## **Pluristem to Present at Needham Healthcare and Oppenheimer Israeli Investment Conferences in May 2013**

HAIFA, Israel, April 30, 2013 -- Pluristem Therapeutics Inc. (NASDAQCM: [PSTI](#)) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today the company is scheduled to participate in the following investment conferences in May 2013:

Event: 12<sup>th</sup> Annual Needham Healthcare Conference  
Date: Wednesday, May 1, 2013  
Time: 10 a.m. Eastern Daylight Time  
Location: The Westin New York Grand Central, New York, NY  
Presenter: William R. Prather RPh, MD Senior VP Corporate Development

Event: 14<sup>th</sup> Annual Oppenheimer Israeli Conference  
Date: Sunday, May 12, 2013  
Time: 12:35 p.m. UTC+2  
Location: David Intercontinental Hotel, Tel Aviv, Israel  
Presenter: Zami Aberman, Chairman and CEO

Investors interested in scheduling a one-on-one meeting during the conferences, please contact us at [info@pluristem.com](mailto:info@pluristem.com).

### **About Pluristem Therapeutics**

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit [www.pluristem.com](http://www.pluristem.com), the content of which is not part of this press release.

### **Safe Harbor Statement**

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

***Contact:***

Pluristem Therapeutics Inc.:

William Prather R.Ph., M.D. Sr. VP Corporate Development  
1-303-883-4954

[William.PratherMD@pluristem.com](mailto:William.PratherMD@pluristem.com)

Daya Lettvin  
Investor & Media Relations Director  
+972-54-674-5580  
[daya@pluristem.com](mailto:daya@pluristem.com)